Regeneron Pharma Price Target Maintained With a $1282.00/Share by RBC Capital
RBC Capital Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,282
RBC Capital analyst Brian Abrahams maintains $Regeneron Pharmaceuticals(REGN.US)$ with a buy rating, and maintains the target price at $1,282.According to TipRanks data, the analyst has a success
BMO Capital Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,300
BMO Capital analyst Evan Seigerman maintains $Regeneron Pharmaceuticals(REGN.US)$ with a buy rating, and maintains the target price at $1,300.According to TipRanks data, the analyst has a success
BofA Securities Initiates Regeneron Pharmaceuticals(REGN.US) With Sell Rating, Announces Target Price $805
BofA Securities analyst Alec Stranahan initiates coverage on $Regeneron Pharmaceuticals(REGN.US)$ with a sell rating, and sets the target price at $805.According to TipRanks data, the analyst has a
Cantor Fitzgerald Reiterates Neutral on Regeneron Pharmaceuticals, Maintains $1015 Price Target
Regeneron Pharmaceuticals Analyst Ratings